{"groups":[{"description":"Patients received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.","id":"FG000","title":"Rituximab + Methotrexate (Group A)"},{"description":"Patients received methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.","id":"FG001","title":"Methotrexate (Group B)"},{"description":"Patients who qualified for re-treatment received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/week orally or subcutaneously. Patients received methylprednisolone 100 mg intravenously before each infusion of rituximab. Patients received no treatment during the Safety Follow-up Period.","id":"FG002","title":"All Patients (Combined Groups A and B)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"}],"type":"Subject/Guardian Decision to Withdraw"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Not Treated with Study Drug"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"69"},{"groupId":"FG001","numSubjects":"34"},{"comment":"Participant Flow is reported separately for the treatment groups for this Period.","groupId":"FG002","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"28"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Treatment Period"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Physician's Decision to Withdraw"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Subject/Guardian Decision to Withdraw"}],"milestones":[{"achievements":[{"comment":"Participant Flow is reported for the combined treatment groups for this Period.","groupId":"FG000","numSubjects":"0"},{"comment":"Participant Flow is reported for the combined treatment groups for this Period.","groupId":"FG001","numSubjects":"0"},{"comment":"Not all patients who completed the Treatment Period entered this Optional Re-treatment Period.","groupId":"FG002","numSubjects":"78"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"72"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"6"}],"type":"NOT COMPLETED"}],"title":"Optional Extension Re-treatment Period"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"5"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Physician Decision to Withdraw"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"12"}],"type":"Subject/Guardian Decision to Withdraw"}],"milestones":[{"achievements":[{"comment":"Participant Flow is reported for the combined treatment groups for this Period.","groupId":"FG000","numSubjects":"0"},{"comment":"Participant Flow is reported for the combined treatment groups for this Period.","groupId":"FG001","numSubjects":"0"},{"comment":"Some patients entered this Safety Follow-up Period directly from the Treatment Period.","groupId":"FG002","numSubjects":"100"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"81"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"19"}],"type":"NOT COMPLETED"}],"title":"Safety Follow-up Period"}]}